Company - OpenAI will begin testing advertisements in ChatGPT to seek new revenue sources [5] - Google has requested a U.S. judge to postpone the order to share data during its appeal [5] - JPMorgan has surpassed Dimensional to become the world's largest active ETF company [6] - Fannie Mae and Freddie Mac continue to decline, raising concerns about their IPO prospects [6] - Spotify plans to generate significant profits through another price increase [6] Industry - The U.S. housing builder confidence index has dropped to 37 in January, marking the first decline in five months and falling below all estimates [5] - The U.S. manufacturing output is expected to grow in the last few months of 2025 [5] - The job market remains a concern, with the Federal Reserve advised to prepare for potential rate cuts [6] - The artificial intelligence sector is accelerating job reductions in key global industries [6] - Oil prices have slightly recovered, but traders remain cautious about risks related to Iran [6]

We recently published 10 Stocks Jim Cramer Talked About.  Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer talked about. Pharma giant Novo Nordisk A/S (NYSE:NVO) created quite the buzz last month after its weight loss pill secured approval from the Food and Drug Administration (FDA), following which the shares jumped by more than 7%. The weight loss pill marked a key win for Novo Nordisk A/S (NYSE:NVO) as the firm has reportedly lagged behind Eli Lilly in the weight loss drug industry. After ...

EU stocks are in focus on Jan. 16 after President Donald Trump signalled plans of slapping tariffs on nations resisting Washington's push to acquire Greenland. "We need Greenland for national security... ...

Novo Nordisk A/S’ (NYSE:NVO) stock is trading higher on Friday as the Wegovy (semaglutide) pill hit 3,071 U.S. prescriptions in the first four days after its launch, Reuters noted, citing IQVIA data.Performance DataWegovy pill showed an average weight loss of about 17% (16.6%) when used along with a reduced-calorie diet and exercise, and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.The weight loss pill was approved in December 2025.The market ‍is closely watching early sales ...

Key Takeaways LLY shares fell 3.8% reportedly as FDA delays decision on oral obesity drug orforglipron.With oral Wegovy already approved, the delay gives NVO extra time to gain share in the obesity pill market.Orforglipron is also in late-stage studies for sleep apnea, osteoarthritis pain and hypertension.Eli Lilly and Company’s (LLY) stock declined 3.8% on Thursday after the FDA reportedly delayed its decision on LLY’s much-awaited oral GLP-1 drug called orforglipron. Reportedly, the FDA delayed its decisi ...

Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company's new GLP-1 pill for obesity.In a Friday note, TD Cowen analysts called it a "solid start" for the first-ever weight loss pill, but said "one data point does not make a trend." They cautioned that they need to see more data to fully assess what early demand is like for the Wegovy pill, which officially launched on Jan. 5 after winning approval in late December. Still ...

每经AI快讯，1月16日，诺和诺德涨逾4.5%。 （文章来源：每日经济新闻） ...

格隆汇1月16日｜诺和诺德(NVO.US)涨超5%报60.3美元。英批准Wegovy7.2毫克高剂量肥胖治疗方案。 另外，分析师周五分享的 IQVIA 数据所显示，诺和诺德旗下减肥药Wegovy口服片剂在美国上市后的前 四天内开出了3071张处方。 ...

周五，诺和诺德(NVO.US)涨逾4%，报59.49美元。消息面上，据报道，英国药品监管机构批准，将诺和 诺德的热门减肥药Wegovy的周最高使用剂量提升至7.2毫克。肥胖患者可分三次注射该剂量。这一更高 剂量方案由英国药品与保健品管理局于1月6日批准，打破了目前2.4毫克的剂量限制，为医生和患者提 供了更广泛的治疗方案选择。 ...

智通财经APP获悉，周五，诺和诺德(NVO.US)涨逾4%，报59.49美元。消息面上，据报道，英国药品监 管机构批准，将诺和诺德的热门减肥药Wegovy的周最高使用剂量提升至7.2毫克。肥胖患者可分三次注 射该剂量。这一更高剂量方案由英国药品与保健品管理局于1月6日批准，打破了目前2.4毫克的剂量限 制，为医生和患者提供了更广泛的治疗方案选择。 ...